International audienceUnderstanding antigen–antibody interactions is important to many emerging medical and bioanalytical applications. In particular, the levels of antigen expression at the cell surface may determine antibody-mediated cell death. This parameter has a clear effect on outcome in patients undergoing immunotherapy. In this context, CD20 which is expressed in the membrane of B cells has received significant attention as target for immunotherapy of leukemia and lymphoma using the monoclonal antibody rituximab. To systematically study the impact of CD20 density on antibody recognition, we designed self-assembled monolayers that display tunable CD20 epitope densities. For this purpose, we developed in situ click chemistry to funct...
Elucidating the underlying mechanisms of cell physiology is currently an important research topic in...
Abstract B-cell Non-Hodgkin lymphomas are the malignancies of lymphocytes. CD20 is a membrane protei...
We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficien...
Understanding antigen-antibody interactions is important to many emerging medical and bioanalytical ...
CD20, expressed in greater than 90% of B-lymphocytic lymphomas, is a target for antibody therapy. Ri...
International audienceMonoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differen...
Reversible binding, for example between signaling molecules and receptors on the cell surface, is on...
Antibody-based therapeutics targeting membrane proteins have evolved as a major modality for the tre...
Cluster of differentiation 20 (CD20) is a B cell membrane protein that is targeted by monoclonal ant...
The chimeric anti-CD20 monoclonal antibody (mAb), rituximab, is an established part of the managemen...
Despite the rapid and widespread integration of chimeric CD20 monoclonal antibody (mAb), rituximab, ...
CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost all normal a...
Understanding molecular interactions on immune cells is crucial for drug development to treat cancer...
CD20 is a cell-surface marker of normal and malignant B cells. Rituximab, a monoclonal antibody targ...
Lay Description In the targeted therapy of B-cell non-Hodgkin lymphoma(NHL), rituximab is a powerful...
Elucidating the underlying mechanisms of cell physiology is currently an important research topic in...
Abstract B-cell Non-Hodgkin lymphomas are the malignancies of lymphocytes. CD20 is a membrane protei...
We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficien...
Understanding antigen-antibody interactions is important to many emerging medical and bioanalytical ...
CD20, expressed in greater than 90% of B-lymphocytic lymphomas, is a target for antibody therapy. Ri...
International audienceMonoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differen...
Reversible binding, for example between signaling molecules and receptors on the cell surface, is on...
Antibody-based therapeutics targeting membrane proteins have evolved as a major modality for the tre...
Cluster of differentiation 20 (CD20) is a B cell membrane protein that is targeted by monoclonal ant...
The chimeric anti-CD20 monoclonal antibody (mAb), rituximab, is an established part of the managemen...
Despite the rapid and widespread integration of chimeric CD20 monoclonal antibody (mAb), rituximab, ...
CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost all normal a...
Understanding molecular interactions on immune cells is crucial for drug development to treat cancer...
CD20 is a cell-surface marker of normal and malignant B cells. Rituximab, a monoclonal antibody targ...
Lay Description In the targeted therapy of B-cell non-Hodgkin lymphoma(NHL), rituximab is a powerful...
Elucidating the underlying mechanisms of cell physiology is currently an important research topic in...
Abstract B-cell Non-Hodgkin lymphomas are the malignancies of lymphocytes. CD20 is a membrane protei...
We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficien...